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Abstract The large rep gene products, Rep78 and Rep68, of 
adeno-associated virus (AAV) are pleiotropic effector proteins 
which are required for AAV DNA replication and the trans- 
regulation of AAV gene expression. Apart from these essential 
functions prerequisite for the life cycle of AAV, these rep prod- 
ucts are able to inhibit the replication and gene expression of 
human immunodeficiency virus type 1 (HIV-1) and a number of 
DNA viruses. Here, it is demonstrated that Rep78, as a chimeric 
with the maltose binding protein, directly binds the full-length 
HIV-I long terminal repeat (LTR), and to a subset of these 
sequences containing the trans-activation response (TAR) se- 
quence as DNA. These interactions, an effector protein physically 
binding a target promoter, suggest a direct mechanism of action 
for Rep78 inhibition. Furthermore, competitive binding studies 
between the TAR region and the full-length HIV-LTR, strongly 
suggested that another site(s) within the LTR was also bound by 
Rep78. Finally, as Rep78 binding is also believed to he affected 
by secondary structure within the DNA, it was found that Rep78 
preferentially binds with HIV-LTR sequences with promoted sec- 
ondary structure generated by heat denaturation and rapid cool- 
ing. 
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I. Introduction 
AAV's life cycle as a human helper-dependent parvovirus 
requires that it interacts with other viruses, and it might gener- 
ally be thought of as a parasite of its helpers, adeno- and herpes 
simplex virus [1,2]. AAV has been found to inhibit a variety of 
viruses, including, adenovirus [3,4], herpes simplex virus [5,6], 
papillomavirus [7-9], and HIV-1 [10-14[. The Rep78 and Rep68 
proteins, encoded by the AAV rep gene, have been found to be 
responsible for these inhibitions [7-9]. Furthermore, Rep78/68 
regulate the expression of cellular genes, including c-H-ras [15 
17], c-fos [18,19], and c-myc [18,19]. These finding are consistent 
with the Rep78/68's function as regulators of AAV's own gene 
expresson. 
Previous studies of AAV's Rep78/68 inhibition of HIV-I 
have concluded that both HIV-1 gene expression and replica- 
tion are inhibited [10-14]. During plasmid co-transfection a d 
micro-injection experiments the wild type AAV genome will 
inhibit HIV-1 replication from 90 to 99%, depending upon the 
particular study. However, Rep78/68 inhibition of HIV-1 gene 
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expression and replication is even stronger when Rep78/68 are 
expressed from the HIV-1 long terminal repeat itself (LTR) 
[12]. Although AAV's inhibition of HIV-1 is well documented, 
the mechanism by which Rep78/68 inhibit HIV-1 has not been 
determined. Rep78/68 are highly multifunctional proteins with 
activities which include covalent and non-covalent binding to 
DNA, ATP-dependent helicase activity, site-specific endonu- 
clease activity, and transcriptional trans-activation and trans- 
repression [20 25]. It is likely that Rep78/68's function as tran- 
scriptional regulators are involved in the mechanism of inhibi- 
tion of HIV-1. 
Thus far, it is believed that the short DNA motif, GCTC, is 
involved in the recognition of DNA by Rep78/68. This se- 
quence is present as a trimeric concatemer in the terminal 
repeats (TR) of AAV and near the site of AAV preferential 
integration on human chromosome 19 [22,23,26-28]. The num- 
ber of GCTC motifs, in close proximity, appear to partially 
determine the affinity of Rep78/68 protein binding [29]. How- 
ever, secondary structure within the DNA also plays a role in 
DNA recognition by Rep78/68. It has been noticed by others 
[11] that the cis TAR sequence of HIV-1, to which the HIV-1 
encoded tat trans-activator binds as RNA, contains multiple 
GCTC motifs [30,31]. This laboratory has been studying Rep78 
functions utilizing a maltose binding protein-Rep78 chimeric 
(MBP-Rep78), produced in bacteria, which has all the known 
biochemical functions of wild type Rep78 from eukaryotes [32]. 
In this study we demonstrate hat MBP-Rep78 is able to bind 
to the TAR region of HIV-I as DNA. 
2. Materials and methods 
2.1. Preparation of DNA substrates and MBP-Rep78 protein 
The AAV TR and murine osteosarcoma virus (MSV)-LTR sub- 
strates (the positive and negative controls for Rep78 binding, respec- 
tively) have been described previously [32], and their sequences are 
shown in Fig. 1. The full-length HIV-LTR substrate (nt -454 to +42) 
was generated by PCR amplification with Taq DNA polymerase, using 
linearized pBennCAT plasmid [33] (BamHI digested) as a template and 
the primers i and ii, shown in Fig. 1. This substrate is referred to as 
HIV-LTR (PCR) and was purified by Qiaquick spin column (Qiagen 
Inc.). Complementary strands of synthetic DNA oligonucleotides 
(oligo)(Operon) ii and iii of Fig. 1 were annealed to generate the TAR A 
substrate (nt +23 to +42). A third HIV-1 DNA substrate was generated 
by PCR amplification utilizing primers iii and iv, and referred to as 
TAR B (+23 to +86). When appropriate, the substrates were labeled 
utilizing polynucleotide kinase and [y-3Zp]ATE The production and 
purification of the chimeric MBP-Rep78 protein used in the study has 
been described elsewhere [32]. 
2.2. PCR amplification 
Amplification was performed in 50 ¢tl reaction mixtures containing 
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50 mM KC1, 10 mM Tris-HC1 pH 8.8, at 25°C, 2 mM MgCl2, 150 mM 
each of dCTER dATER dGTP and dTTP, 100 pmol of both primers 
(shown in Fig. 1), 1 ng of template (BamH I linearized pBennCAT), and 
2.5 units of Taq DNA polymerase (Promega, Madison, WI) overlaid 
with mineral oil. The first denaturing step was performed at 94°C for 
2 min. A total of 30 cycles were performed with a denaturing tempera- 
ture at 92°C for 40 s, annealing at 60°C for 40 s and extension for 1.5 
min at 75°C. Final extension was performed for 5 min. The PCR 
product was purified by Qaiquick spin column (Qiagen Inc.). 
2.3. Electrophoretic mobility shift assay (EMSA ) 
EMSA assays were conducted as described previously with minor 
modifications [34]. Approximately 1 ng of 5' end-labeled DNA sub- 
strate was incubated with increasing amounts of MBP-Rep78 for 10 
rain at room temperature in binding buffer [(25 mM HEPES KOH pH 
7.5, 10 mM MgC12, 1 mM dithiothreiotol, 2% glycerol, 25 ,ug bovine 
serum albumin, 50 mM NaC1, 0.01% NP40 and 0.5 ¢tg poly (cliniC)]. 
Samples were electrophoresed in a 4% polyacrylamide gel (40:1 
acrylamide and bis-acrylamide weight ratio) with 5% glycerol in 0.5 x 
TBE buffer at 100 V for about 3 h. Gels were dried and autoradiogra- 
phed at -70°C. Addition of increasing amounts of MBP-Rep78 is 
indicated in the figure legend. To promote DNA secondary structure 
formation in the HIV-LTR (PCR) substrate was boiled for 2 rain and 
chilled immediately on ice as described by others [35]. Experiments 
involving competition between radiolabeled substrate and unlabeled 
substrate were carried out as indicated in the specific figure. 
3. Results 
3.1. MBP-Rep78 binds" to the full-length HIV-LTR 
With the knowledge that Rep78 recognizes GCTC motifs (or 
its complement, GAGC)  it was observed that the HIV-LTR 
contained 8 of these motifs. Fig. 1 shows the sequences of the 
HIV-LTR, the GCTC motifs, and the HIV-1 derived synthetic 
DNA oligonucleotides used in this study. To determine 
whether Rep78 bound anywhere within the full-length HIV- 
LTR, the sequences from nt -454 to nt +42 were amplified by 
polymerase chain reaction (PCR) and tested in an electro- 
phoretic mobility shift assay (EMSA) for binding with a Rep78/ 
maltose binding protein chimeric, MBP-Rep78. This chimeric 
MBP-Rep78 protein has identical biochemical activities to that 
of the fully wild type Rep78 in all assays o far attempted (DNA 
binding, helicase, endonuclease activity, etc.) [25,26]. As shown 
in Fig. 2 the MBP-Rep78 protein was able to bind the HIV- 
LTR (PCR) as indicated by the appearance of a new high 
shifted band which was dependent of the amount of MBP- 
Rep78 added to the reaction. This interaction of the effector 
molecule with the target promoter DNA suggests a direct 
mechanism of action for AAV Rep78 inhibition of HIV replica- 
tion and gene expression. The MBP protein did not bind this 
or any other DNA (data not shown). 
3.2. MBP-Rep78 binds the HIV TAR DNA sequences 
One region of the HIV-LTR was of particular interest as it 
contained three GCTC motifs (nt +25 to +38, motifs 1-3, Fig. 
1 B) in close proximity. This area corresponds to the cis TAR 
region, which is where the HIV-1 encoded tat trans-regulatory 
protein binds as an mRNA sequence, resulting in > 100-fold 
AAV TR: (positive control) 
t 1 5 ...G14~AACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTC°GCTC2GCTC ACTGAGG(;.es 
MSV-LTR: (negative control) 
5'...C.ssTGTACCCGCGCTTATTGCTGCCCAGCTClTATAAAAAGGGTAAGAACCCCACACTCGGCG,1 
HIV-LTR: 
5 ' T.4e,GGAAGGGCTAATTCACTCCC.434AACGAAGACAAGATATCCTTGATCTGTGGATCTACCACA 
CACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCT 
TTGGATGGTGCTACAAGCTAGTACCAGTTGAGCeCAGATAAGGTAGAAGAGGCCAATAAAGGAGAG 
AA CACCAGCTTGTTACACCCTGTGAGC7CTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGA 
GTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGG CCCGA GA GCeTGCATCGGGAGTACTTCAA 
GAACTGCTGATATCGAGCr'TTGCTACAAGGGAC-I-TTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCT 
GGGCGGGACTGGGGAGTGGCGAGC~CCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTG 
~'* G ,1GTCTCTCTGGTTAGACCAGATC , 2~T GAGC3CTGGGAGC2TClTCTG +42GCTAGCTAGGGAACC 
CACTGC,e~TTAAGCCTCAATAAAGCTGCCTT, e e 3' 
HIV-1 oligonucleotides: 
i 5' TGGAAGGGCTAATTCACTCCC 
ii 5' CAGAGAGCTCCCAGGCTCAG 
iii 5' CTGAGCCTGGGAGCTCTCTG 
iv 5' AAGGCAGCTTTATTGAGGCTTAAG 
Fig. 1. Sequences of the DNA substrates and synthetic oligonucleotides u ed in this study. At the top of the figure are sequences from the AAV TR 
and murine osteosarcomavirus (MSV) LTR. The underlined bases represent substrate sequences. The motifs GCTC and GAGC are in italics, bolded 
and identified by superscript numbers. The AAV TR and MSV-LTR substrates were used as the positive and negative controls, respectively [29]. 
Also shown are the sequences of the HIV-1 LTR. The underlined bases in the HIV-LTR represent substrate sequences and/or PCR primers used 
to generate substrates. The nucleotide positions relative to the transcription i itiation site (bent arrow) of the HIV-LTR promoter are denoted by 
subscript numbers. The oligonucleotides i and ii were used to PCR generate the HIV-LTR (PCR) substrate (nt -454 to +42). The oligonucleotides 
ii and iii were used together (complementary) as the TAR A oligonucleotide substrate (nt +23 to +42), which encompasses the TAR sequences. The 
oligonucleotides iii and iv were used to PCR generate the TAR B substrate (Nt +23 to +86). The plasmid pBennCAT was the PCR template. 
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MBP-Rep78 (pgs) 0 .1 .2 .4 
HIV-LTR (PCR) + + + + 
tion and called TAR B (from nt +23 to +86) utilizing oligonucle- 
otides iii and iv (Fig. 1A). TAR B did not contain any additional 
GCTC motifs over TAR a. When assayed in the EMSA, the 
TAR B sequence also was recognized by MBP-Rep78, and at a 
slightly elevated level compared to TAR A (Fig. 3). 
Fig. 2. Dosage dependent complex formation between HIV-LTR DNA 
sequences and MBP-Rep78 protein. Note that increasing amounts of 
the band shifted MBP-Rep781HIV-LTR (PCR) complex appear with 
increasing amounts of MBP-Rep78. The HIV-LTR substrate (nt -454 
to +42) was generated by PCR amplification with Taq DNA polym- 
erase, using linearized pBennCAT plasmid (BamHI digested) as a tem- 
plate and the primers i and ii, shown in Fig. 1. MBP-Rep78 protein 
production and purification has been described previously [32]. EMSA 
assays were conducted as described insection 2. Briefly, 1 ng of 32p-5'- 
labeled HIV-LTR (PCR) was incubated with increasing amounts of 
MBP-Rep78 for 10 min at room temperature in binding buffer. Samples 
were electrophoresed in a4% polyacrylamide g l, dried and autoradi- 
ographed. Addition of increasing amounts of MBP-Rep78 indicated 
above the panel. 
3.3. Competition studies between the full-length HIV-LTR 
(PCR) and the TAR A oligonucleotide substrate suggest 
that MBP-Rep78 is binding to additional sites within the 
HIV-LTR 
As five other GCTC motifs are present within the HIV-LTR, 
in addition to those in the TAR region, the possibility that the 
TAR A sequences were the major binding site for Rep78 within 
the HIV-LTR was investigated by EMSA competition studies. 
The small TAR A duplex substrate was used as a unlabeled 
competitor against Rep78 binding with the full-length 32p-la- 
beled HIV-LTR (PCR generated). The AAV TR and MSV- 
LTR synthetic duplex DNAs were also used as control compe- 
titors (positive and negative controls, respectively). As expected 
the AAV TR was an effective competitor, while the MSV-LTR 
was ineffective (Fig. 4A). TAR A was also a very weak compet- 
itor. TAR A was next compared irectly with the full-length 
HIV-LTR (PCR generated) for effectiveness a a competitior 
(Fig. 4B). As expected the HIV-LTR competed effectively 
against itself, while TAR A did not. These data are consistent 
with the hypothesis that Rep78 is also binding to other regions 
of the HIV-LTR, possibly other GCTC motifs, and with higher 
infinity than to the TAR region. 
3.4. MBP-Rep78 preferentially binds to HIV-LTR substrates 
with promoted secondary structure 
As mentioned previously, it has been reported that Rep78168 
protein binding to DNA subtrates i accentuated if those sub- 
strates have significant secondary structure, as with the AAV 
TR which will form a cruciform structure [26]. To determine 
higher expression levels [30,31]. This laboratory has previously 
demonstrated that a region of the c-H-ras promoter, with a 
similar three motif architecture, was able to bind an MBP-Rep 
protein chimeric [2]. To observe if sequences from the TAR 
region of the HIV-LTR were able to bind MBP-Rep78, a syn- 
thetic duplex DNA oligonucleotide substrate (Fig. 1A, ii and 
iii, and C from nt +23 to +42, referred to as TAR a, was used 
as a substrate for MBP-Rep78 recognition i  an EMSA (Fig. 
3). The results show that MBP-Rep78 does bind the TAR A 
sequences, asindicated by a shifted band. However, the affinity 
of MBP-Rep78 for TAR a was at an intermediate l vel com- 
pared to the AAV TR (positive control, the natural substrate 
for Rep78, with 3 GCTC motifs in a concatemeric arrangement 
[29]) and a selected sequence from the MSV-LTR (negative 
control, one GCTC motif [29], also referred to as 'MSV'). 
In addition to the three GCTC motifs present in the AAV 
TR's stem, the secondary structure of the TRs, with multiple 
hairpin loops, are believed to play a role in the recognition and 
binding affinity of Rep78. Furthermore, this laboratory has 
demonstrated binding to a single duplex DNA GCTC motif 
within the context of a DNA hairpin [28]. The DNA sequence 
of the HIV-1 TAR region also shows the potential for signifi- 
cant secondary structure in the region from nt -1 to +82. To 
investigate whether Rep78 bound to this larger TAR sequence, 
a substrate larger than TAR A was generated by PCR amplifica- 
DNAs: TAR A M$V TR TAR B 
MBP-Rep78.2 .1  0 .2 .1  0 .2 .1  0 .2 .1  0 
(pgs) 
Fig. 3. Analysis of MBP-Rep78 binding to HIV TAR DNA. Note that 
a band shifted protein-DNA complex appears in both the TAR A and 
TAR B lanes indicating MBP-Rep78 binding to TAR. Approximately 
1 ng of the indicated 32p-5"-labeled substrate was incubated in the 
reaction. The TR and MSV-LTR are the positive and negative controls, 
respectively. EMSA assay was performed as mentioned inFig. 2 with 
a 5% polyacrylamide g l. 
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ng TAR A oligo 
competitor 0 01020100 0 0 0 0 0 0 0 0 0 0 
ng AAV TR oligo 
competitor 0 0 0 0 0 0 0 10201000 0 0 0 0 
ng MSV oligo 
competitor 0 0 0 0 0 0 0 0 0 0 0 0 10 20100 
MBP-Rep78 + + + + + + + + - + + + + 
HIV-LTR(PCR) + + + + + + + + + + + + + + + 
A 
ng compet i to r :  
H IV -LTR(PCR)  0 0 1020 100  0 0 0 0 0 
TARA o l igo  0 0 0 0 0 0 01020 100  
MBP-Rep78 - + + + + + + + + 
H IV -LTR(PCR)  + + + + + + + + + + 
B 
Fig. 4. Competition studies between the HIV-LTR and other DNA 
substrates for Rep78 binding. (A) Competition studies between 32p 
5'-labeled and unlabeled HIV-LTR (PCR) and with unlabeled TAR A, 
for MBP,Rep78 binding activity. Note that the HIV-LTR (PCR) is a 
better competitor than TAR A. Increasing amounts of unlabeled ol- 
igonucleotide competitors were added in the EMSA assay as indicated 
with equal amounts of MBP-Rep78 protein (500 ng). Approximately 
1 ng of 32p-5'-labeled HIV-LTR (PCR) substrate was incubated in every 
reaction. (B) Competition studies between 32p-5'-labeled HIV-LTR 
(PCR) and unlabeled AAV terminal repeat (TR) or the MSV-LTR 
oligonucleotides for MBP-Rep78 binding. Note that the AAV TR ol- 
igonucleotide is an effective competitor when compared to the MSV- 
LTR oligonucleotides or the TAR A oligonucleotide. Increasing 
amounts of unlabeled oligonucleotide competitors were added in the 
EMSA assay as indicated with equal amounts of MBP-Rep78 protein 
(500 ng). Approximately 1 ng of 32p-5' end-labeled HIV-LTR (PCR) 
substrate was incubated in every reaction. 
if secondary structure had an affect on MBP-Rep78 recognition 
of the full-length HIV-LTR, the HIV-LTR (PCR) substrate 
was heat denatured and quick-chilled on ice to generate 'snap 
back' secondary hairpin structures [35]. This 'snap back' HIV- 
LTR substrate was compared to normal duplex HIV-LTR 
(PCR) for Rep78 binding in an EMSA (Fig. 5). As shown in 
Fig. 5, the normal duplex and 'snap back' HIV-LTR (PCR) 
substrates migrated at different positions in the gel so that it 
was possible to distinguish between them. In one set of reac- 
tions equal amounts of the 'snap back' substrate and normal 
duplex substrate were added together in the EMSA. Both the 
normal duplex and the 'snap back' HIV-LTR (PCR) substrates 
were able to bind MBP-Rep78. However, when the duplex and 
'snap back' substrates were together in the same reaction tube 
the 'snap back' substrate was preferentially band shifted by 
MBP-Rep78 demonstrating a higher affinity for this substrate. 
4. Discussion 
HIV infection is a global problem with no effective treat- 
ment. The inhibitory properties of AAV (Rep78) on HIV-1 
replication and gene expression have been well documented, 
however, the specific mechanism of action is unknown. Our 
results demonstrate hat the Rep78 trans-effector protein phys- 
ically binds to target promoter sequences. Although the func- 
tional implications of Rep78 binding to TAR DNA (not TAR 
RNA to which tat binds) of the HIV-LTR are still unknown, 
these results suggest a direct mechanism of action for Rep78 
trans-regulation of HIV. Rittner et al. (1992) have previously 
predicted that the Rep78/68 proteins may bind to specific se- 
quences of the HIV-LTR [11]. Our data supports their hypoth- 
esis. The sequences of the HIV TAR oligonucleotides (Fig. 1) 
which we have shown binding to MBP-Rep78 are nearly iden- 
tical to those predicted sequences. Possible detailed mecha- 
nisms for Rep78 inhibition may include the following: (i) the 
steric hindrance by Rep78 of the binding of important positive 
trans-regulators (e.g. tat), (ii) the signalling of other, more di- 
rect, effectors of negative trans-regulation, (iii) the direct inter- 
action and effect of Rep78 with the RNA polymerase II com- 
plex of proteins, or (iv) the physical disruption of the HIV-1 
DNA sequences by the Rep78 endonuclease function. 
The inability of TAR A to effectively compete against the 
full-length HIV-LTR (PCR) suggests that Rep78 is binding to 
additional sites within the HIV-LTR and with higher affinity 
than Rep78 recognition of TAR. Preliminary experiments in
this laboratory are consistent with Rep78 strongly binding to 
another site within the HIV-1 LTR, near TAR (Batchu and 
Hermonat, unpublished). Furthermore, this study demon- 
strates that the HIV-LTR, with promoted secondary structure 
generated by rapid denaturation/renaturation, is preferentially 
bound by Rep78. These finding are consistent with studies of 
Rep78/68 binding to the AAV TR and to sequences from the 
c-H-ras promoter [20-23,29]. To what extent hese secondary 
stuctures actually form in vivo is unknown and predicting the 
extent and importance of the these structures would be highly 
spectulative. However, the 'snap back' form may have rele- 
vance to HIV-1 gene expression as some transcription factors 
are known to recognize interrupted palindromes which have 
the potential to generate secondary structures (e.g. the papillo- 
mavirus E2 trans-activator which recognizes the sequence 
ACCN6GGT [36]. 
Continuing these studies we intend to uncover Rep78's 
mechanism of action for inhibiting HIV-1. Ultimately, it is 
hoped that AAV Rep78 may be used as a treatment for HIV 
infection. As a gene therapy vector, another interesting area of 
AAV research [37], AAV is able to transduce bone marrow 
progenitor cells [38]. By placing the Rep78 gene under the 
regulation of an HIV responsive promoter and then transduc- 
ing hematopoietic progenitor cells, it may be possible to con- 
struct an HIV resistant immune system, by generating intracel- 
lular immunization. 
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HIV-LTR (PCR):  
dup lex  + + + - - + + + 
snap back  - - + + + + + + 
ugsMBP-Rep78 0 .15  .3 0 .3 .15  0 .15  .3 
Fig. 5. Preferential binding of MBP-Rep78 with promoted secondary structure of HIV-LTR DNA compared to the same substrate without such 
promoted structures. Note that the HIV-LTR (PCR) with promoted secondary structure, the higher band compared to the normal duplex, disappears 
first with the addition of MBP-Rep78 protein. The HIV-LTR (PCR) was subjected to over 100°C for 2 min and quickly chilled on ice to form a 
'snap back' secondary structure prior to the EMSA assay. Approximately 1 ng of labeled HIV-LTR (PCR) was used in the study. When normal 
duplex and promoted secondary structure HIV-LTR (PCR) were both added into one reaction, 0.5 ng of each substrate was used. 
Acknowledgements: The authors wish to thank Drs. Wayne Gray, Rick 
Drake, and Bill Stroop for reviewing this manuscript. This research was 
supported by a grant, a Medical Research Endowment Award, from 
the University of Arkansas Foundation Fund to RL.H.R.B.B. is a 
Daland fellow of the American Philosophical Society. The authors wish 
to thank Dr. Peter Howley for the plasmid pBennCAT. 
References 
[1] Buller, R.M., Janik, J.E., Subring, E.D. and Rose, J.A. (1981) 
J. Virol. 40, 241 247. 
[2] Casto, B.C., Atchinson, R.W. and Hammon, W.McD. (1967) 
Virology 18, 52 60. 
[3] Kirchstein, R.L., Smith, K.O. and Peters, E.A. (1968) Proc. Soc. 
Exp. Biol. Med. 128, 670-674. 
[4] Casto, B.C., Atchinson, R.W. and Hammon, W.McD. (1967) 
Virology 18, 52 60. 
[5] Cukor, G., Blacklow, N.R., Kibrick, S. and Swan, I.C.J. Natl. 
Can. Inst. 55, 957 959. 
[6] Blacklow, N.R., Cukor, G., Kibrick, S. and Quinnan, G. (1978) 
in: Replication of Mammalian Parvovirues (D.C. Ward and E 
Tattersal, Eds.) pp. 87-97. 
[7] Hermonat, P.L. (1989) Virology 172, 253-261. 
[8] Hermonat, P.L. (1992) Virology 189, 329-333. 
[9] Hermonat, EL. (1994) Cancer Res. 54, 2278-2281 
[10] Oelze, I., Rittner, K. and Sczakiel, G. (1994) J. Virol. 68, 1229- 
1233. 
[11] Rittner, K., Heilbronn, R., Kleinschmidt, J.A. and Sczakiel, G. 
(1992) J, Gen. Virol. 73, 2977-2981. 
[12] Antoni, B.A., Rabson, A.B., Miller, I.L., Trempe, J.P, 
Chejanovsky, N. and Carter, B.J. (1991) J. Virol. 64, 396-404. 
[13] Rittner, K., Heilbronn, R., Kleinschmidt, J.A., Oelze, I. and 
Sczakiel, G. (1991) Biochem. Soc. Transact. 19, 438S. 
[14] Mendelson, E., Grossman, E, Mileguir, F., Rechavi, G. and 
Carter, B.J. (1992) Virology 187, 453-463. 
[15] Katz, E. and Carter, B.J. (1986) Cancer Res. 46, 3023-3026. 
[16] Hermonat, P.L. (1991) Can. Res. 1 51, 3373-3377. 
[17] Khleif, S.N., Myers, T., Carter, B.J. and Trempe. J P. (1991) Virol- 
ogy 181, 738-741. 
[18] Hermonat, EL. (1994) Cancer Lett. 81, 129-136. 
[19] Klein-Bauernschmitt, P. zur Hausen, H. and Schlehofer, J.R. 
(1992) J. Virol. 66, 4191-4200. 
[20] Im, D.S. and Muzyczka, N. (1989) Cell 61,447-457, 
[21] Im, D.S. and Muzyczka, N. (1992) J. Virol. 66, 1119 1128. 
[22] Snyder, R.O., Im, D.-S., Ni, T., Xiao, X., Samulski, R.J., 
Muzyczka, N. (1993) J. Virol. 67, 6096-6104. 
[23] Snyder, R.O., Im, D.S., Muzyczka, N. (1990) J. Virol. 64, 6204- 
6213. 
[24] Labow, M.A., Hermonat, EL. and Berns, K.I. (1986) J. Virol. 60, 
251-258. 
[25] Tratschin, J.D., Tal, J. and Carter, B.J. (1986) Mol. Cell Biol. 6, 
2884-2894. 
[26] Weitzman, M.A., Kyostio, S.R.M., Kotin, R.M. and Owens, R.A. 
(1994) Proc. Natl. Acad. Sci. USA 91, 5808-5812. 
[27] Samulski, R.J., Zhu, X., Brook, J.D., Housman, D.E., Epstein, N. 
and Hunter, L.A. (1991) EMBO. J. 10, 3941-3950.31. 
[28] Kotin, R.M., Linden, R.M. and Berns, K.I. (1992) EMBO. J. 11, 
5071-5078. 
[29] Batchu, R.B., Kotin, R.M. and Hermonat, EL. (1994) Can. Lett. 
86, 23 31. 
[30] Hauber, J. and Cullen, B. (1988) J. Virol. 62, 673-679. 
[31] Rosen, C.A., Sodroski, J.G. and Haseltine, W.A. (1988) Cell 41, 
813 823. 
[32] Batchu, R.B., Miles, D.A., Rechtin, T.M., Drake, R.R. and 
Hermonat, EL. (1995) Biochem. Biophy. Res. Commun. 208,714- 
720 
[33] Gendelman, H.E. et al. (1986) Proc. Natl. Acad. Sci. USA 89, 
975%9763. 
[34] Berkhout, B., Silverman, R.H. and Jeang, K.T. (1989) Cell 59, 
273-282. 
[35] Willwand, K. and Hirt, B. (1991) J. Virol. 65, 4269-4235. 
[36] Spalholz, B.A., Yang, Y.C. and Howley, P.M. (1985) Cell 42, 
183-191. 
[37] Hermonat, P.L. and Muzyczka, N. (1984) Proc. Natl. Acad. Sci. 
USA 81, 6466-6470. 
[38] La Face, D., Hermonat, P., Wakeland., E. and Peck., A (1988) 
Virology 162, 483-486. 
